HER-2-positive metastatic breast cancer: Trastuzumab and beyond

Research output: Contribution to journalArticle

Abstract

Background: The recognition achieved in the late 1980s of human epidermal growth factor receptor 2 as an appealing therapeutic target for breast cancer has led to the development of targeted therapies for patients with human epidermal growth factor receptor 2-overexpressing breast tumors. Objectives: The aim of the present review is to address the standard treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer patients, which is currently based on the humanized monoclonal antibody trastuzumab and to describe the new treatment options available for patients progressing on trastuzumab-based therapies. Methods: A broad literature research was performed in order to review treatments, starting from the developmental phase of trastuzumab to the most recent biologic agents being tested in human epidermal growth factor receptor 2-positive disease. Results: Trastuzumab combined with a taxane represents the first therapeutic option for human epidermal growth factor receptor 2-positive metastatic breast cancer. However, novel combinations of trastuzumab and chemotherapy still hold great interest for their remarkable activity and good tolerability. On the other hand, the dual epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor lapatinib has been the first drug to be approved in combination with capecitabine for the treatment of patients who progress on trastuzumab-based therapies. Moreover, in the near future, trastuzumab plus another biologic agent targeting human epidermal growth factor receptor 2, either directly or indirectly, may represent an effective 'chemotherapy-free' combination for trastuzumab-refractory patients.

Original languageEnglish
Pages (from-to)2583-2601
Number of pages19
JournalExpert Opinion on Pharmacotherapy
Volume9
Issue number15
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Breast Neoplasms
Therapeutics
Biological Factors
Combination Drug Therapy
Antibodies, Monoclonal, Humanized
Trastuzumab
human ERBB2 protein
Epidermal Growth Factor Receptor
Research
Pharmaceutical Preparations

Keywords

  • Bevacizumab
  • Human epidermal growth factor receptor 2
  • Lapatinib
  • Metastatic breast cancer
  • Pertuzumab
  • Trastuzumab

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

HER-2-positive metastatic breast cancer : Trastuzumab and beyond. / Metro, Giulio; Mottolese, Marcella; Fabi, Alessandra.

In: Expert Opinion on Pharmacotherapy, Vol. 9, No. 15, 10.2008, p. 2583-2601.

Research output: Contribution to journalArticle

@article{c22a6eb8b0e7479798704df7d683a771,
title = "HER-2-positive metastatic breast cancer: Trastuzumab and beyond",
abstract = "Background: The recognition achieved in the late 1980s of human epidermal growth factor receptor 2 as an appealing therapeutic target for breast cancer has led to the development of targeted therapies for patients with human epidermal growth factor receptor 2-overexpressing breast tumors. Objectives: The aim of the present review is to address the standard treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer patients, which is currently based on the humanized monoclonal antibody trastuzumab and to describe the new treatment options available for patients progressing on trastuzumab-based therapies. Methods: A broad literature research was performed in order to review treatments, starting from the developmental phase of trastuzumab to the most recent biologic agents being tested in human epidermal growth factor receptor 2-positive disease. Results: Trastuzumab combined with a taxane represents the first therapeutic option for human epidermal growth factor receptor 2-positive metastatic breast cancer. However, novel combinations of trastuzumab and chemotherapy still hold great interest for their remarkable activity and good tolerability. On the other hand, the dual epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor lapatinib has been the first drug to be approved in combination with capecitabine for the treatment of patients who progress on trastuzumab-based therapies. Moreover, in the near future, trastuzumab plus another biologic agent targeting human epidermal growth factor receptor 2, either directly or indirectly, may represent an effective 'chemotherapy-free' combination for trastuzumab-refractory patients.",
keywords = "Bevacizumab, Human epidermal growth factor receptor 2, Lapatinib, Metastatic breast cancer, Pertuzumab, Trastuzumab",
author = "Giulio Metro and Marcella Mottolese and Alessandra Fabi",
year = "2008",
month = "10",
doi = "10.1517/14656566.9.15.2583",
language = "English",
volume = "9",
pages = "2583--2601",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "15",

}

TY - JOUR

T1 - HER-2-positive metastatic breast cancer

T2 - Trastuzumab and beyond

AU - Metro, Giulio

AU - Mottolese, Marcella

AU - Fabi, Alessandra

PY - 2008/10

Y1 - 2008/10

N2 - Background: The recognition achieved in the late 1980s of human epidermal growth factor receptor 2 as an appealing therapeutic target for breast cancer has led to the development of targeted therapies for patients with human epidermal growth factor receptor 2-overexpressing breast tumors. Objectives: The aim of the present review is to address the standard treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer patients, which is currently based on the humanized monoclonal antibody trastuzumab and to describe the new treatment options available for patients progressing on trastuzumab-based therapies. Methods: A broad literature research was performed in order to review treatments, starting from the developmental phase of trastuzumab to the most recent biologic agents being tested in human epidermal growth factor receptor 2-positive disease. Results: Trastuzumab combined with a taxane represents the first therapeutic option for human epidermal growth factor receptor 2-positive metastatic breast cancer. However, novel combinations of trastuzumab and chemotherapy still hold great interest for their remarkable activity and good tolerability. On the other hand, the dual epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor lapatinib has been the first drug to be approved in combination with capecitabine for the treatment of patients who progress on trastuzumab-based therapies. Moreover, in the near future, trastuzumab plus another biologic agent targeting human epidermal growth factor receptor 2, either directly or indirectly, may represent an effective 'chemotherapy-free' combination for trastuzumab-refractory patients.

AB - Background: The recognition achieved in the late 1980s of human epidermal growth factor receptor 2 as an appealing therapeutic target for breast cancer has led to the development of targeted therapies for patients with human epidermal growth factor receptor 2-overexpressing breast tumors. Objectives: The aim of the present review is to address the standard treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer patients, which is currently based on the humanized monoclonal antibody trastuzumab and to describe the new treatment options available for patients progressing on trastuzumab-based therapies. Methods: A broad literature research was performed in order to review treatments, starting from the developmental phase of trastuzumab to the most recent biologic agents being tested in human epidermal growth factor receptor 2-positive disease. Results: Trastuzumab combined with a taxane represents the first therapeutic option for human epidermal growth factor receptor 2-positive metastatic breast cancer. However, novel combinations of trastuzumab and chemotherapy still hold great interest for their remarkable activity and good tolerability. On the other hand, the dual epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor lapatinib has been the first drug to be approved in combination with capecitabine for the treatment of patients who progress on trastuzumab-based therapies. Moreover, in the near future, trastuzumab plus another biologic agent targeting human epidermal growth factor receptor 2, either directly or indirectly, may represent an effective 'chemotherapy-free' combination for trastuzumab-refractory patients.

KW - Bevacizumab

KW - Human epidermal growth factor receptor 2

KW - Lapatinib

KW - Metastatic breast cancer

KW - Pertuzumab

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=55249119148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249119148&partnerID=8YFLogxK

U2 - 10.1517/14656566.9.15.2583

DO - 10.1517/14656566.9.15.2583

M3 - Article

C2 - 18803447

AN - SCOPUS:55249119148

VL - 9

SP - 2583

EP - 2601

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 15

ER -